Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
co-trimoxazole
- Development stage
- Phase 4
- Lead developer
- Aleppo Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALPHATRIM FORTE is an oral fixed-dose combination of the sulfonamide antibiotic sulfamethoxazole and the dihydrofolate reductase inhibitor trimethoprim, collectively known as co-trimoxazole. Developed by Aleppo Pharmaceutical, it is approved for the treatment of various bacterial infections, including urinary tract infections, bronchitis, and middle ear infections. Sulfamethoxazole acts as a competitive inhibitor of dihydropteroate synthase (DHPS), blocking the conversion of para-aminobenzoic acid (PABA) to dihydropteroate. Trimethoprim inhibits bacterial dihydrofolate reductase (DHFR), preventing the reduction of dihydrofolate to tetrahydrofolate. Together, these two agents exert a synergistic bactericidal effect by sequentially blocking two consecutive steps in the bacterial biosynthesis of essential nucleic acids and proteins.
- Brand names
- ALPHATRIMALPHATRIM FORTE
- Other names
- sulfamethoxazole + trimethoprimsulfamethoxazole-trimethoprimtrimethoprim + sulfamethoxazoletrimethoprim-sulfamethoxazole
02
Targets
DHFR (Dihydrofolate reductase)DHFR-TS (Bifunctional dihydrofolate reductase-thymidylate synthase)DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on co-trimoxazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on co-trimoxazole.